| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1002/BIES.950180810 |
| P698 | PubMed publication ID | 8760340 |
| P2093 | author name string | D B Wigley | |
| R J Lewis | |||
| F T Tsai | |||
| P2860 | cites work | Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth | Q35718618 |
| DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa | Q39780359 | ||
| Biological characterization of cyclothialidine, a new DNA gyrase inhibitor | Q39883723 | ||
| Mechanism of inhibition of DNA gyrase by cyclothialidine, a novel DNA gyrase inhibitor | Q40286248 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 661-71 | |
| P577 | publication date | 1996-08-01 | |
| P1433 | published in | BioEssays | Q4914614 |
| P1476 | title | Molecular mechanisms of drug inhibition of DNA gyrase | |
| P478 | volume | 18 |
| Q47823727 | A plastid organelle as a drug target in apicomplexan parasites. |
| Q37120952 | Antimicrobial and DNA gyrase-inhibitory activities of novel clorobiocin derivatives produced by mutasynthesis. |
| Q36702934 | Biological activities of novel gyrase inhibitors of the aminocoumarin class |
| Q46458071 | Bone-targeting of quinolones conjugated with an acidic oligopeptide |
| Q34579744 | Burkholderia cenocepacia conditional growth mutant library created by random promoter replacement of essential genes |
| Q22121990 | Cellular roles of dna topoisomerases: a molecular perspective |
| Q44387030 | Clorobiocin biosynthesis in Streptomyces: identification of the halogenase and generation of structural analogs. |
| Q36178767 | Competitive Growth Enhances Conditional Growth Mutant Sensitivity to Antibiotics and Exposes a Two-Component System as an Emerging Antibacterial Target in Burkholderia cenocepacia |
| Q61039329 | Dibenzo[1,6]naphthyridindiones as modified quinolone antibacterials |
| Q34150441 | Enabling the chemistry of life |
| Q35188962 | Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents |
| Q34214929 | Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. |
| Q73829736 | Fluoroquinolones |
| Q24674283 | Glutamate racemase from Mycobacterium tuberculosis inhibits DNA gyrase by affecting its DNA-binding |
| Q42724331 | GyrI: a counter-defensive strategy against proteinaceous inhibitors of DNA gyrase |
| Q31115766 | Mechanism of action-based classification of antibiotics using high-content bacterial image analysis |
| Q38335859 | Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage |
| Q73692196 | Monoclonal antibodies to mycobacterial DNA gyrase A inhibit DNA supercoiling activity |
| Q37092384 | Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives |
| Q38327429 | Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions. |
| Q37320252 | Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket |
| Q47108181 | Physiological Roles of DNA Double-Strand Breaks |
| Q35044119 | Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. |
| Q37329087 | Selective drug delivery to bone using acidic oligopeptides |
| Q41965305 | Simultaneous estimation of degree of crystallinity in combination drug product of abacavir, lamivudine and neverapine using X-ray powder diffraction technique. |
| Q46651773 | Structure of DNA topoisomerases |
| Q38313313 | The additional 165 amino acids in the B protein of Escherichia coli DNA gyrase have an important role in DNA binding |
| Q39927053 | The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity |
| Q42166139 | The effect of topoisomerase II inhibitors on the kinetoplast ultrastructure. |
| Q38523119 | Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin. |
| Q42710319 | Tricyclic sesquiterpenes from Vetiveria zizanoides (L.) Nash as antimycobacterial agents |
| Q41728284 | Type II DNA topoisomerases |
| Q48015411 | Validation of Putative Apicoplast-Targeting Drugs Using a Chemical Supplementation Assay in Cultured Human Malaria Parasites. |
Search more.